|
|
Article: Bendamustine: a novel cytotoxic agent for hematologic malignancies.(Clinical report)
- Article from:
- Clinical Journal of Oncology Nursing
- Article date:
- October 1, 2008
- Author:
CopyrightCOPYRIGHT 2008 Oncology Nursing Society. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Bendamustine hydrochloride (Treanda[R], Cephalon, Inc.) is a novel bifunctional mechlorethamine derivative approved in March 2008 by the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic lymphocytic leukemia (CLL) (Cephalon, Inc., 2008). Trials in the United States recently have been completed studying its use as monotherapy (Friedberg et al., 2008) and in combination with rituximab in patients with relapsed or refractory non-Hodgkin lymphoma (NHL) (Robinson et al., 2008). It currently is under FDA review for the treatment of patients with indolent NHL who have progressed during or following treatment with rituximab or a ...